Drug Guidance for Subsidy 04/06/2024 Calcitonin gene-related peptide (CGRP) monoclonal antibodies for prophylaxis of migraine The Ministry of Health’s Drug Advisory Committee has recommended: Galcanezumab 120 mg/mL solu... See all × 04/06/2024 Calcitonin gene-related peptide (CGRP) monoclonal antibodies for prophylaxis of migraine The Ministry of Health’s Drug Advisory Committee has recommended: Galcanezumab 120 mg/mL solution for injection in pre-filled pen for prophylaxis of migraine in adults who have at least four migraine days a month prior to commencement of treatment with galcanezumab. Patients must have experienced an inadequate response, intolerance, or a contraindication to at least three migraine prophylactic medications. Treatment with galcanezumab should be stopped after 12 weeks if: a) in episodic migraine, the number of migraine days per month does not reduce by at least 50% compared with baseline; b) in chronic migraine, the number of migraine days per month does not reduce by at least 30% compared with baseline. Funding status RGalcanezumab 120 mg/mL solution for injection in pre-filled pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024. NRMAF assistance does not apply to galcanezumab 100 mg/mL solution for injection in pre-filled syringe, or any formulations or strengths of eptinezumab, erenumab or fremanezumab.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Vyepti Infusion, Solution Concentrate 100 mg/mL Tan Tock Seng Hospital
INTRAVENOUS DRIP Select a brand starting with the letter: V VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML [SIN16325P]